Alvotech (ALVO), a commercial-stage global biotech company specializing in the development and manufacture of biosimilar medicines, is making steady progress in its pipeline to drive future growth and diversification.
A biosimilar is a biological medicine that is highly similar to and has no clinically meaningful differences from an existing approved biological, or reference product. The first biosimilar drug approved in the U.S. was Zarxio, a biosimilar of Neupogen, developed by Sandoz/Novartis, which received the regulatory nod on March 6, 2015. Since then, the FDA has approved a total of 64 biosimilars, with the latest being Steqeyma, a biosimilar to Stelara, from Celltrion USA, approved on December 17, 2024.
For comments and feedback: editorial@rttnews.com